Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults

Inclusion Criteria: * Male or female adults (≥18 yrs) * Stable health status * Provide informed consent * Access to direct phone service (NOT a pay phone or a common-use phone service) * Eligible females must have a negative pregnancy test Exclusion Criteria: * Febrile illness (\>38.0°C oral temperature) * High blood pressure (≥140/90 mmHg) * Significant acute or chronic * Uncontrolled medical or psychiatric illness within 1 month prior to vaccination * Immunosuppressive condition (confirmed or suspected) * Renal impairment * Hepatic dysfunction * Complicated insulin-dependent diabetes mellitus * Unstable cardiopulmonary disease * Blood dyscrasias * Cytotoxic, immunosuppressive drug, or glucocorticoids use within 1 month of vaccination (nasal glucocorticoids allowed) * History of demyelinating disease * Active neurological disorder * Significant alcohol or drug abuse * Significant coagulation disorder (prophylactic antiplatelet medications allowed) * Influenza vaccine administrated within 6 months prior to study vaccination * Administration of any other vaccine from 30 days prior to the end of the study * Use of non-registered drug within 30 days prior to study vaccination * Receipt of immunoglobulins and/or any blood products within 3 months of study vaccination * History or suspected allergy to previous influenza vaccine, or to any constituent of FluLaval™ TR and Fluarix®, or reaction to eggs consumption * Pregnant or nursing female subjects * Female subjects not protected by an acceptable contraception method (except if surgically sterile or post-menopausal)